After many years, many mosquitoes, many generous human volunteers, and countless hours of work by the Seattle Malaria Clinical Trials Center, the Fred Hutch, the University of Washington, Seattle Children's Research Institute and other partners, our publication on the prophylactic efficacy of the novel antimalarial drug KAF156 is now accepted and online in Clinical Infectious Diseases (click for link). Doses as low at 100 mg protected against controlled human malaria infection, and the drug was safe and well tolerated. We'll see what happens next for this potent antimalarial.
Comments are closed.
|
Lab PostUpdates about lab activities, papers and other insights! Archives
April 2024
Categories |